BACKGROUND: B cell activation may result in an increased secretion of immunoglobulin free light chains (FLCs) in autoimmune diseases. OBJECTIVE: To analyse serum FLC levels in patients with rheumatoid arthritis and in those with primary Sjögren's syndrome (pSS). PATIENTS AND METHODS: Blood samples were collected from 80 healthy blood donors, 50 patients with rheumatoid arthritis and 139 patients with pSS. Serum FLC level was measured using a new quantitative immunoassay. RESULTS: Mean (standard error (SE)) serum kappa and lambda FLC levels were significantly higher in patients with rheumatoid arthritis and in those with pSS than in controls (kappa : 18.9 (1.1) and 16.3 (1.4) v 10.5 (0.4) mg/l, p<0.001 and p = 0.001, respectively; lambda: 16.7 (1.2) and 19.3 (1.5) v 11.6 (0.6) mg/l, p<0.001 for both). 18 (36%) patients with rheumatoid arthritis and 31 (22.3%) patients with pSS had abnormal serum FLC levels (increased kappa or lambda levels and abnormal ratio of kappa:lambda). Serum kappa and lambda levels were correlated with other B cell activation markers in both diseases. FLC levels increased with disease activity, because, unlike total gammaglobulin and immunoglobulin G levels, they were significantly correlated with Disease Activity Score 28 in patients with rheumatoid arthritis (p = 0.004 for kappa, p = 0.05 for lambda) and with extraglandular involvement in pSS (p = 0.01 for kappa, p = 0.04 for lambda). CONCLUSION: FLC levels are increased and correlate with disease activity in patients with rheumatoid arthritis and in those with pSS, two diseases in which increased risk of lymphoma could result from persistent B cell activation and disease activity. Further studies are required to determine whether FLC assessment could represent a relevant biomarker for response to treatment (especially B cell depletion) and for the risk of lymphoma in autoimmune diseases.
BACKGROUND: B cell activation may result in an increased secretion of immunoglobulin free light chains (FLCs) in autoimmune diseases. OBJECTIVE: To analyse serum FLC levels in patients with rheumatoid arthritis and in those with primary Sjögren's syndrome (pSS). PATIENTS AND METHODS: Blood samples were collected from 80 healthy blood donors, 50 patients with rheumatoid arthritis and 139 patients with pSS. Serum FLC level was measured using a new quantitative immunoassay. RESULTS: Mean (standard error (SE)) serum kappa and lambda FLC levels were significantly higher in patients with rheumatoid arthritis and in those with pSS than in controls (kappa : 18.9 (1.1) and 16.3 (1.4) v 10.5 (0.4) mg/l, p<0.001 and p = 0.001, respectively; lambda: 16.7 (1.2) and 19.3 (1.5) v 11.6 (0.6) mg/l, p<0.001 for both). 18 (36%) patients with rheumatoid arthritis and 31 (22.3%) patients with pSS had abnormal serum FLC levels (increased kappa or lambda levels and abnormal ratio of kappa:lambda). Serum kappa and lambda levels were correlated with other B cell activation markers in both diseases. FLC levels increased with disease activity, because, unlike total gammaglobulin and immunoglobulin G levels, they were significantly correlated with Disease Activity Score 28 in patients with rheumatoid arthritis (p = 0.004 for kappa, p = 0.05 for lambda) and with extraglandular involvement in pSS (p = 0.01 for kappa, p = 0.04 for lambda). CONCLUSION: FLC levels are increased and correlate with disease activity in patients with rheumatoid arthritis and in those with pSS, two diseases in which increased risk of lymphoma could result from persistent B cell activation and disease activity. Further studies are required to determine whether FLC assessment could represent a relevant biomarker for response to treatment (especially B cell depletion) and for the risk of lymphoma in autoimmune diseases.
Authors: C Vitali; S Bombardieri; R Jonsson; H M Moutsopoulos; E L Alexander; S E Carsons; T E Daniels; P C Fox; R I Fox; S S Kassan; S R Pillemer; N Talal; M H Weisman Journal: Ann Rheum Dis Date: 2002-06 Impact factor: 19.103
Authors: S Bernatsky; J F Boivin; L Joseph; R Rajan; A Zoma; S Manzi; E Ginzler; M Urowitz; D Gladman; P R Fortin; M Petri; S Edworthy; S Barr; C Gordon; S C Bae; J Sibley; D Isenberg; A Rahman; C Aranow; M A Dooley; K Steinsson; O Nived; G Sturfelt; G Alarcón; J L Senécal; M Zummer; J Hanly; S Ensworth; J Pope; H El-Gabalawy; T McCarthy; Y St Pierre; R Ramsey-Goldman; A Clarke Journal: Arthritis Rheum Date: 2005-05
Authors: Roshini S Abraham; Jerry A Katzmann; Raynell J Clark; A R Bradwell; Robert A Kyle; Morie A Gertz Journal: Am J Clin Pathol Date: 2003-02 Impact factor: 2.493
Authors: Jerry A Katzmann; Raynell J Clark; Roshini S Abraham; Sandra Bryant; James F Lymp; Arthur R Bradwell; Robert A Kyle Journal: Clin Chem Date: 2002-09 Impact factor: 8.327
Authors: F Gulli; C Napodano; M Marino; G Ciasca; K Pocino; V Basile; M Visentini; A Stefanile; L Todi; M De Spirito; G L Rapaccini; U Basile Journal: Clin Exp Immunol Date: 2019-10-31 Impact factor: 4.330
Authors: Y Murata; K Aoe; Y Mimura-Kimura; T Murakami; K Oishi; T Matsumoto; H Ueoka; K Matsunaga; M Yano; Y Mimura Journal: Clin Exp Immunol Date: 2017-07-17 Impact factor: 4.330
Authors: Carsten P Bramlage; Britta Froelich; Manuel Wallbach; Joan Minguet; Clemens Grupp; Cornelia Deutsch; Peter Bramlage; Gerhard A Müller; Michael Koziolek Journal: Rheumatol Int Date: 2017-02-18 Impact factor: 2.631
Authors: L Chiche; J M Cournac; J Mancini; N Bardin; G Thomas; R Jean; N Schleinitz; G Kaplanski; J M Durand; J Boucraut; J R Harlé Journal: Clin Rheumatol Date: 2011-01-11 Impact factor: 2.980
Authors: Normann Steiner; Georg Göbel; Daniela Michaeler; Anna-Luise Platz; Wolfgang Prokop; Anna Maria Wolf; Dominik Wolf; Christina Duftner; Eberhard Gunsilius Journal: Blood Adv Date: 2021-03-23
Authors: Carsten Paul Bramlage; Britta Froelich; Manuel Wallbach; Joan Minguet; Clemens Grupp; Cornelia Deutsch; Peter Bramlage; Michael Koziolek; Gerhard Anton Müller Journal: Clin Rheumatol Date: 2016-10-12 Impact factor: 2.980